公开(公告)号：US20050048053A1

公开(公告)日：2005-03-03

申请号：US10808538

申请日：2004-03-25

申请人： Shui-on Leung ,  Michele Losman ,  Hans Hansen

发明人： Shui-on Leung ,  Michele Losman ,  Hans Hansen

IPC分类号： C12N15/09 ,  A61K31/00 ,  A61K39/00 ,  A61K39/395 ,  A61K49/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/04 ,  C07K16/42 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/574 ,  C07H21/04 ,  C07K16/30 ,  C12N5/06

CPC分类号： C07K16/3007 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/4266 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2319/00

摘要： A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotype also can be used as an immunogenic vaccine.

摘要翻译： CEA的抗独特型抗体（例如hWI2）的人源化形式具有保守的免疫反应性。 通过使用人源化抗独特型作为抗CEA抗体或抗体片段的清除剂，抗CEA抗体的临床益处最大化。 人源化抗独特型也可用作免疫原性疫苗。

公开(公告)号：US20050002945A1

公开(公告)日：2005-01-06

申请号：US10776470

申请日：2004-02-11

申请人： William McBride ,  David Goldenberg ,  Carl Noren ,  Hans Hansen

发明人： William McBride ,  David Goldenberg ,  Carl Noren ,  Hans Hansen

IPC分类号： A61K47/48 ,  A61K51/04 ,  A61K51/08 ,  A61K51/10 ,  C07K7/06 ,  C07K16/18 ,  C07K16/30 ,  C07K16/44 ,  C07K16/46 ,  A61K39/00

CPC分类号： A61K51/0497 ,  A61K47/665 ,  A61K51/04 ,  A61K51/0455 ,  A61K51/048 ,  A61K51/1048 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K5/06078 ,  C07K5/1013 ,  C07K5/1016 ,  C07K5/1019 ,  C07K7/06 ,  C07K16/18 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/00

摘要： Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer/carrier, or both. The effector molecule may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. Also disclosed are methods of synthesizing the compounds and/or precursors of the compounds.

摘要翻译： 公开了包含两个或多个通过间隔物或载体缀合的半抗原的化合物。 半抗原可以包括二亚乙基三胺五乙酸（DTPA），组氨酰胺 - 琥珀酰 - 谷氨酰胺（HSG）或DTPA和HSG的组合。 化合物还包括效应分子，其可以与一个或多个半抗原，间隔物/载体或两者结合。 效应分子可以通过多个键连接，包括酯键，亚氨基键，氨基键，硫键，硫代缩氨基脲键，缩氨基脲键，肟键，醚键或这些键的组合。 还公开了合成化合物的化合物和/或前体的方法。

公开(公告)号：US06187287B1

公开(公告)日：2001-02-13

申请号：US09127902

申请日：1998-08-03

申请人： Shui-on Leung ,  Hans Hansen

发明人： Shui-on Leung ,  Hans Hansen

IPC分类号： A61K4900

CPC分类号： C07K16/3061 ,  A61K38/00 ,  A61K47/6851 ,  A61K47/6867 ,  A61K47/6877 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/77 ,  C07K2319/00

摘要： A chimeric LL2 monoclonal antibody is described in which the complementarity determining regions (CDRs) of the light and heavy chains of the murine LL2 anti-B-lymphoma, anti-leukemia cell monoclonal antibody has been recombinantly joined to the human kappa and IgG1 constant region domains, respectively, which retains the immunospecificity and B-cell lymphoma and leukemia cell internalization capacity of the parental murine LL2 monoclonal antibody, and which has the potential of exhibiting reduced human anti-mouse antibody production activity. A humanized LL2 monoclonal antibody is described in which the CDRs of the light and heavy chains have been recombinantly joined to a framework sequence of human light and heavy chains variable regions, respectively, and subsequently linked to human kappa and IgG1 constant region domains, respectively, which retains the immunospecificity and B-lymphoma and leukemia cell internalization capacities of the parental murine and chimeric LL2 monoclonal antibodies, and which has the potential for exhibiting reduced human anti-mouse antibody production activity. Vectors for producing recombinant chimeric and humanized chimeric monoclonal antibodies are provided. Isolated DNAs encoding the amino acid sequences of the LL2 variable light and heavy chain and CDR framework regions are described. Conjugates of chimeric and humanized chimeric LL2 antibodies with cytotoxic agents or labels find use in therapy and diagnosis of B-cell lymphomas and leukemias.

摘要翻译： 描述了嵌合LL2单克隆抗体，其中鼠LL2抗B淋巴瘤，抗白血病细胞单克隆抗体的轻链和重链的互补决定区（CDR）已经重组连接到人类κ和IgG1恒定区 分别保留亲本鼠LL2单克隆抗体的免疫特异性和B细胞淋巴瘤和白血病细胞内化能力，其具有降低的人抗小鼠抗体生产活性的潜力。 描述了一种人源化的LL2单克隆抗体，其中轻链和重链的CDR分别重组连接到人轻链和重链可变区的框架序列上，并分别与人类κ和IgG1恒定区结构域连接， 其保留亲本鼠和嵌合LL2单克隆抗体的免疫特异性和B淋巴瘤和白血病细胞内化能力，并且其具有降低的人抗小鼠抗体产生活性的潜力。 提供了用于产生重组嵌合和人源化嵌合单克隆抗体的载体。 描述了编码LL2可变轻链和重链和CDR构架区的氨基酸序列的分离的DNA。 具有细胞毒性剂或标签的嵌合和人源化嵌合LL2抗体的缀合物可用于B细胞淋巴瘤和白血病的治疗和诊断。

公开(公告)号：US5199349A

公开(公告)日：1993-04-06

申请号：US905827

申请日：1992-06-26

申请人： Hans Hansen

发明人： Hans Hansen

IPC分类号： A47J43/28

CPC分类号： A47J43/284

摘要： A skimmer/separator ladle comprises a handle of an elongated configuration and a bowl of a cup-shaped configuration defining an upper rim. The handle and the bowl are connected together and the handle extends upwardly from the bowl at the upper rim of the bowl. In order to render it possible to carry out any skimming/separation operation, the bowl has an outwardly protruding tongue arranged at a first rim section of the bowl, which tongue is located below the upper rim of the bowl, and further one or more through-going holes which are provided in the bowl and arranged at a second rim section of the bowl, which one or more through-going holes are located below the upper rim of the bowl and further located above the tongue.

摘要翻译： 撇渣器/分离器浇包包括细长构型的手柄和限定上边缘的杯形构型的碗。 手柄和碗连接在一起，手柄从碗的上边缘向上延伸。 为了使得可以执行任何撇取/分离操作，碗具有布置在碗的第一边缘部分处的向外突出的舌部，该舌部位于碗的上边缘下方，并且还有一个或多个穿过 所述孔设置在所述碗中并且布置在所述碗的第二边缘部分处，所述一个或多个贯通孔位于所述碗的上边缘下方并且还位于所述舌部的上方。